US EditionUS FDA approves higher dose of Novo's Wegovy
The FDA approved Wegovy HD after trials showed up to 21% weight loss at 72 weeks; availability in U.S. pharmacies starts in April.
- The FDA announced Thursday that it approved a 7.2-milligram Wegovy HD injectable, expanding the label for adults with overweight and obesity, Novo Nordisk said on March 19, 2026.
- After launching an oral Wegovy pill earlier this year, the company developed the 7.2 mg dose because some patients do not reach therapeutic goals on the Wegovy 2.4-milligram dose, and it aims to better compete with Zepbound.
- In the STEP UP trial, semaglutide 7.2 mg produced an average 20.7% weight loss at 72 weeks, with 31.2% losing 25% or more and 89% achieving at least 5% versus 38% on placebo.
- The FDA granted approval after a 54-day review, marking the first GLP-1 approval under the FDA national priority voucher pilot plan with accelerated approval based on STEP UP and STEP UP T2D trials.
31 Articles
31 Articles
FDA greenlights higher-dose GLP-1 obesity shots
The Food and Drug Administration approved a higher-dose version of a popular class of obesity drugs on Thursday, the latest expansion in a rapidly growing market for weight-loss treatments. The newly authorized dose of Novo Nordisk’s Wegovy increases the maximum weekly injection from 2.4 milligrams to 7.2 milligrams, offering patients a stronger option if they have not achieved the desired results with existing therapies. Federal regulators cle…
High-Dose Wegovy Wins FDA Approval
(MedPage Today) -- The FDA approved a higher dose of the GLP-1 receptor agonist semaglutide for weight loss, dubbed Wegovy HD, the agency announced on Thursday. The once-weekly injectable will come in a 7.2-mg dose -- three times the strength...
FDA approves high-dose Wegovy 7.2 mg for adults with obesity
The FDA approved a higher 7.2 mg dose of injectable semaglutide for adults with overweight and obesity, Novo Nordisk announced. Once-weekly injectable semaglutide 7.2 mg (Wegovy HD, Novo Nordisk) received accelerated approval based on findings from the STEP UP and STEP UP T2D trials. As Healio previously reported, adults with obesity but without type 2 diabetes receiving semaglutide 7.2 mg in
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
